Barinthus Biotherapeutics plc annual stock-based compensation
2020
2021
2022
2023
2024
2025
Barinthus Biotherapeutics plc Stock-Based Compensation Growth & History (BRNS)
Barinthus Biotherapeutics plc's stock-based compensation was $468,000 for fiscal 2025.
View full Barinthus Biotherapeutics plc company overviewBarinthus Biotherapeutics plc annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $468,000 | −$4.2M | −90.06% |
| 2024 | 2024-12-31 | $4.7M | −$346,000 | −6.84% |
| 2023 | 2023-12-31 | $5.1M | −$4.8M | −48.82% |
| 2022 | 2022-12-31 | $9.9M | −$6.6M | −40.09% |
| 2021 | 2021-12-31 | $16.5M | $12.9M | +354.81% |
| 2020 | 2020-12-31 | $3.6M | — | — |
Barinthus Biotherapeutics plc quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $433,000 | $714,000 | — |
| Q1 2026 | 2026-03-31 | $556,000 | $88,000 | +18.80% |
| Q4 2025 | 2025-12-31 | $696,000 | −$59,000 | −7.81% |
| Q3 2025 | 2025-09-30 | −$415,000 | −$1.6M | — |
| Q2 2025 | 2025-06-30 | −$281,000 | −$1.5M | — |
| Q1 2025 | 2025-03-31 | $468,000 | −$1.1M | −71.02% |
| Q4 2024 | 2024-12-31 | $755,000 | −$31,000 | −3.94% |
| Q3 2024 | 2024-09-30 | $1.1M | $1.1M | +1907.02% |
| Q2 2024 | 2024-06-30 | $1.2M | −$795,000 | −39.95% |
| Q1 2024 | 2024-03-31 | $1.6M | −$607,000 | −27.32% |
| Q4 2023 | 2023-12-31 | $786,000 | −$1.3M | −61.49% |
| Q3 2023 | 2023-09-30 | $57,000 | −$1.0M | −94.84% |
| Q2 2023 | 2023-06-30 | $2.0M | −$758,000 | −27.58% |
| Q1 2023 | 2023-03-31 | $2.2M | −$1.8M | −44.23% |
| Q4 2022 | 2022-12-31 | $2.0M | −$1.5M | −42.99% |
| Q3 2022 | 2022-09-30 | $1.1M | −$2.3M | −67.28% |
| Q2 2022 | 2022-06-30 | $2.7M | −$6.0M | −68.54% |
| Q1 2022 | 2022-03-31 | $4.0M | $3.2M | +399.87% |
| Q4 2021 | 2021-12-31 | $3.6M | $1.4M | +62.73% |
| Q3 2021 | 2021-09-30 | $3.4M | $3.2M | +2090.91% |
| Q2 2021 | 2021-06-30 | $8.7M | $8.3M | +2005.06% |
| Q1 2021 | 2021-03-31 | $797,000 | −$59,000 | −6.89% |
| Q4 2020 | 2020-12-31 | $2.2M | — | — |
| Q3 2020 | 2020-09-30 | $154,000 | — | — |
| Q2 2020 | 2020-06-30 | $415,000 | — | — |
| Q1 2020 | 2020-03-31 | $856,000 | — | — |
Barinthus Biotherapeutics plc stock-based compensation trends
Over the last five fiscal years, Barinthus Biotherapeutics plc's stock-based compensation decreased from $3.6M to $468,000, a change of −$3.2M. The latest reported quarter, Q2 2026, shows $433,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Barinthus Biotherapeutics plc source filings ↗